NCT05960968 Gender Specific Registry in Subjects Hospitalized With Heart Failure in Santiago
| NCT ID | NCT05960968 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fundacion de la Sociedad Chilena de Cardiologia y Cirugia Cardiovascular |
| Condition | Heart Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-08-11 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2023-08-11 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational registry, which main purpose is to assess sex-related differences in heart failure (HF) presentation, management, and prognosis in patients admitted to a hospital with a certain diagnosis of HF. The diagnosis will be based on European Society of Cardiology (ESC) definition of HF ( clinical syndrome characterized by symptoms and/or signs caused by a cardiac abnormality, that results in elevated intracardiac pressure and/or inadequate output at rest or exercise ). The sample will be obtained prospectively by recruitment of patients of two hospitals of Santiago de Chile.
Eligibility Criteria
Inclusion criteria: * Patient with ≥ 18 years old * Signed informed consent * Admitted to the hospital with a : * 1\) diagnosis of acute HF as the leading cause of admission, and in which a CV therapy is needed and prescribed (ie. diuretic, vasodilator, inotropic, device), or * 2\) diagnosis of chronic HF is established during the patient hospitalization based on clinical, biochemical and/or imaging studies, and in which cardiovascular therapy is needed and prescribed (ie. diuretic, vasodilator, inotropic, device ) during the hospitalization. Exclusion criteria: * The patient presents a Covid 19 acute infection and/ or severe acute respiratory syndrome (SARS) -CoV 2 pneumonia is confirmed * The patient presents a psychiatric decompensated disorder and/or a cognitive impairment which preclude assessment of this survey.
Contact & Investigator
PAOLA VARLETA, MD
PRINCIPAL INVESTIGATOR
Fundacion de la Sociedad Chilena de Cardiologia y Cirugia Cardiovascular
Frequently Asked Questions
Who can join the NCT05960968 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05960968 currently recruiting?
Yes, NCT05960968 is actively recruiting participants. Contact the research team at pao.varleta@gmail.com for enrollment information.
Where is the NCT05960968 trial being conducted?
This trial is being conducted at Santiago, Chile.
Who is sponsoring the NCT05960968 clinical trial?
NCT05960968 is sponsored by Fundacion de la Sociedad Chilena de Cardiologia y Cirugia Cardiovascular. The principal investigator is PAOLA VARLETA, MD at Fundacion de la Sociedad Chilena de Cardiologia y Cirugia Cardiovascular. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.